Philippe Truelle, President of CDM Lavoisier, highlights the financial impact of the EU’s Falsified Medicines Directive (FMD) on SMEs across Europe and explains how France is becoming increasingly attractive to foreign investors under the Macron Presidency. He also speaks out about CDM Lavoisier’s longstanding legacy in France and outlines the company’s ambitious expansion plans.
One can say France is back, however, there is still a lot of work to do, as we have been losing expertise and manufacturing capacities to other countries during the past 15 years
